These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23287335)

  • 21. Tardive laryngeal dystonia associated with aripiprazole monotherapy.
    Matsuda N; Hashimoto N; Kusumi I; Ito K; Koyama T
    J Clin Psychopharmacol; 2012 Apr; 32(2):297-8. PubMed ID: 22388164
    [No Abstract]   [Full Text] [Related]  

  • 22. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study.
    Ryu S; Yoo JH; Kim JH; Choi JS; Baek JH; Ha K; Kwon JS; Hong KS
    J Clin Psychopharmacol; 2015 Feb; 35(1):13-21. PubMed ID: 25485636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Paroxysmal motor manifestations in multiple sclerosis].
    Castaigne P; Cambier J; Masson M; Brunet P; Lechevallier B; Delaporte P; Dehen H
    Presse Med (1893); 1970 Oct; 78(44):1921-4. PubMed ID: 5474986
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of tardive dystonia with an antispastic agent.
    Nisijima K; Shimizu M; Ishiguro T
    Acta Psychiatr Scand; 1998 Oct; 98(4):341-3. PubMed ID: 9821458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Akathisia in the course of olanzapine treatment].
    Makkos Z; Csonka A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):215-7. PubMed ID: 17211056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of tardive pharyngolaryngeal dystonia with olanzapine.
    Havaki-Kontaxaki BJ; Kontaxakis VP; Christodoulou GN
    Schizophr Res; 2004 Feb; 66(2-3):199-200. PubMed ID: 15061257
    [No Abstract]   [Full Text] [Related]  

  • 27. Tardive dystonia induced by switch of atypical antipsychotics.
    Chen CC; Chen YY; Hung GC
    Pharmacopsychiatry; 2010 Jul; 43(5):200-1. PubMed ID: 20486043
    [No Abstract]   [Full Text] [Related]  

  • 28. Oxcarbazepine as an adjunct for schizophrenia.
    Leweke FM; Gerth CW; Koethe D; Faulhaber J; Klosterkotter J
    Am J Psychiatry; 2004 Jun; 161(6):1130-1. PubMed ID: 15169712
    [No Abstract]   [Full Text] [Related]  

  • 29. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant treatment of schizophrenic illness with carbamazepine].
    Hesslinger B; Klose P; Normann C; Langosch JM; Berger M; Walden J
    Fortschr Neurol Psychiatr; 1998 Apr; 66(4):145-50. PubMed ID: 9587773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in intractable tardive dystonia in bipolar disorder after aripiprazole treatment: a case report.
    Takagai S; Nakasato K; Suzuki K; Kasai E; Isogai S; Morimoto S; Mori N
    J Clin Psychopharmacol; 2012 Aug; 32(4):563-4. PubMed ID: 22760347
    [No Abstract]   [Full Text] [Related]  

  • 32. Olanzapine in schizophrenia and affective disorders.
    Undurraga J; Vieta E; Tohen M; Colom F
    Drug Saf; 2012 Dec; 35(12):1185-6; author reply 1186. PubMed ID: 23137154
    [No Abstract]   [Full Text] [Related]  

  • 33. Olanzapine-associated pica in a schizophrenia patient.
    Huang JH; Shiah IS; Lee WK; Tzang RF; Chang KJ
    Psychiatry Clin Neurosci; 2010 Aug; 64(4):444. PubMed ID: 20653915
    [No Abstract]   [Full Text] [Related]  

  • 34. [Risk factors for tardive movement disorders in schizophrenia].
    Tenback DE; Bakker PR; van Harten PN
    Tijdschr Psychiatr; 2015; 57(2):120-4. PubMed ID: 25669950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
    Lerner PP; Miodownik C; Lerner V
    Psychiatry Clin Neurosci; 2015 Jun; 69(6):321-34. PubMed ID: 25556809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.
    Jhirwal OP; Parsad D; Basu D
    Int J Dermatol; 2004 Oct; 43(10):778-9. PubMed ID: 15485541
    [No Abstract]   [Full Text] [Related]  

  • 37. Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.
    Yang SY; Liao YT; Liu HC; Chen WJ; Chen CC; Kuo CJ
    J Clin Psychiatry; 2013 Jan; 74(1):e79-86. PubMed ID: 23419234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine-induced acute pancreatitis.
    Baysal B; Kayar Y; Özmen A; ElShobaky M; Mahdi N; İnce AT; Danalıoğlu A; Şentürk H
    Turk J Gastroenterol; 2015 May; 26(3):289-90. PubMed ID: 26006214
    [No Abstract]   [Full Text] [Related]  

  • 39. [Abnormal movements of psychogenic origin: usefulness of the readiness potential].
    Casez O; Vercueil L
    Rev Neurol (Paris); 2006 Jun; 162(6-7):770-2. PubMed ID: 16840990
    [No Abstract]   [Full Text] [Related]  

  • 40. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.